65,437 trials
Colorectal Neoplasms · Metastases · Neoplasm
Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.59; -0.03 Percent — p=<0.001
Crohn's Disease
Primary: Mean Extent of Exposure - Duration in Days — 159.2 days
Fibromyalgia Syndrome
Primary: Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set) — -1.30; -1.80 Score on a scale
Hypertension
Primary: Unexpected Adverse Events — 0.58 Percentage of patients
Preventive Oral Health
Primary: Mean Percentage of Correct Skills — 73; 87 Percentage of correct skills
Alcohol Drinking · Smoking · Marijuana Smoking
Primary: Self-reported 30-day Use of Alcohol — 330; 332 Participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -1.7; -1.4 percent
Healthy
Primary: Maximum Plasma Concentration(Cmax) — 4,240.65; 4,521.20 ng/mL
Allergic Asthma
Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Hypercholesterolemia
Primary: Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48) — 135.05; 140.79 ng.h/mL
Pancreaticobiliary Reflux
Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl
Schizophrenia
Primary: Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint. — 2.5; 2.3; 2.4 Points on a scale — p=<0.001
Healthy Subjects · Pharmacokinetics · Bioavailability
Primary: Area Under the Plasma Concentration Versus Time Data Pairs at Steady State (AUCss) — 5991; 6399 ng*h/mL